Company profile: Cardiff Oncology
1.1 - Company Overview
Company description
- Provider of oncology therapeutics targeting cell division, including onvansertib, a PLK1 inhibitor evaluated with standard-of-care treatments for cancers such as metastatic colorectal cancer and pancreatic ductal adenocarcinoma; includes Clinical Trial CRDF-004 assessing onvansertib with standard care in KRAS- or NRAS-mutated metastatic colorectal cancer.
Products and services
- Clinical Trial CRDF-004: Genotype-specific clinical study assessing safety and efficacy of onvansertib plus standard care for KRAS/NRAS-mutated metastatic colorectal cancer
- Onvansertib (metastatic colorectal cancer): Clinical-stage PLK1 inhibitor developed for combination with standard-of-care therapeutics to treat metastatic colorectal cancer by targeting cell division
- Onvansertib (pancreatic ductal adenocarcinoma): PLK1-targeted therapeutic evaluated alongside standard-of-care regimens for pancreatic ductal adenocarcinoma to interfere with tumor cell division
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cardiff Oncology
Insure One
HQ: United States
Website
- Description: Provider of at-home fecal immunochemical tests (FIT) for colorectal cancer screening, using a non-invasive brush-based sample collection to detect lower gastrointestinal bleeding without direct stool handling, with a focus on patient compliance and data privacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insure One company profile →
Lightpoint Medical
HQ: United Kingdom
Website
- Description: Provider of intraoperative imaging technology for real-time cancer detection during surgery, including Cerenkov Luminescence Imaging (CLI) to reduce recurrence and reoperation; offers SENSEI®, a miniature gamma probe for minimally-invasive and robot-assisted procedures to detect radiation and guide surgeons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lightpoint Medical company profile →
Onxeo
HQ: France
Website
- Description: Provider of oncology drug R&D and platforms, offering Beleodaq (belinostat), a histone deacetylase inhibitor marketed in the US for injection; Livatag, a nanoparticle doxorubicin in Phase III for primary liver cancer; and pipeline programs including platON, a decoy oligonucleotide platform for cancer and inflammatory diseases; AsiDNA, a DNA-repair decoy; and VIO-01, a pan‑DDR decoy activating STING.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onxeo company profile →
Forty Seven
HQ: United States
Website
- Description: Provider of clinical-stage immuno-oncology therapies targeting cancer immune evasion pathways, based on technology licensed from Stanford University. Lead program 5F9 is a monoclonal antibody against the CD47 receptor, a 'don't eat me' signal that cancer cells commandeer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forty Seven company profile →
Delcath Systems
HQ: United States
Website
- Description: Provider of interventional oncology therapies for metastatic liver cancer, including HEPZATO KIT for adult patients with metastatic uveal melanoma using a hepatic delivery system; the CHEMOSAT Hepatic Delivery System for melphalan for percutaneous hepatic perfusion to treat liver cancers; and Percutaneous Hepatic Perfusion, a minimally invasive procedure delivering high-dose chemotherapy directly to the liver while isolating the organ from the body’s circulatory system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delcath Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cardiff Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cardiff Oncology
2.2 - Growth funds investing in similar companies to Cardiff Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cardiff Oncology
4.2 - Public trading comparable groups for Cardiff Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →